Diagnostic and Therapeutic Approach for Hypertensive Patients with Suspected TB Adenitis

Diagnostic Workup

The Centers for Disease Control and Prevention recommends obtaining tissue diagnosis through excisional biopsy or fine-needle aspiration of the affected lymph node to confirm TB adenitis through histopathology showing granulomatous inflammation with caseous necrosis and mycobacterial culture 1, 2, 3
The World Health Organization suggests submitting at least 3 serial samples from the lymph node site when possible to maximize diagnostic yield, and performing both AFB smear microscopy and mycobacterial culture on all specimens, with culture being the gold standard 4, 5

The American Thoracic Society recommends initiating four-drug therapy immediately once tissue diagnosis is obtained or if clinical suspicion is high while awaiting culture results, with a treatment regimen consisting of isoniazid, rifampicin, pyrazinamide, and ethambutol for 2 months, followed by isoniazid and rifampicin for 4 months 1, 2, 3
The European Respiratory Society suggests that the total treatment duration should be at least 6 months, with rifampicin 10 mg/kg daily, pyrazinamide 25 mg/kg daily, and ethambutol 15 mg/kg daily during the initial phase, and isoniazid 5 mg/kg daily and rifampicin 10 mg/kg daily during the continuation phase 3

The European Respiratory Society recommends monitoring treatment response monthly through clinical assessment and, if applicable, repeat imaging of lymph nodes, and performing liver function tests every 2-4 weeks during treatment to detect hepatotoxicity 3, 6
The Centers for Disease Control and Prevention suggests administering pyridoxine (vitamin B6) with isoniazid to prevent peripheral neuropathy, and implementing directly observed therapy (DOT) to ensure adherence 3, 6

The World Health Organization recommends performing rapid molecular drug susceptibility testing for rifampicin if the patient has prior TB treatment history, was born in or lived ≥1 year in a high TB incidence country, or has known contact with drug-resistant TB, and consulting a TB expert for management of multi-drug resistant TB (resistance to at least isoniazid and rifampicin) 5